129 related articles for article (PubMed ID: 24637549)
1. Chemoprevention for neurofibromatosis 2: just over the horizon?
Plotkin SR
Neuro Oncol; 2014 Apr; 16(4):471-2. PubMed ID: 24637549
[No Abstract] [Full Text] [Related]
2. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
3. Medicine. A common pathway for a rare disease?
Vafai SB; Mootha VK
Science; 2013 Dec; 342(6165):1453-4. PubMed ID: 24357304
[No Abstract] [Full Text] [Related]
4. Inhibition of TORC1 signaling and increased lifespan: gained in translation?
Rallis C; Bähler J
Aging (Albany NY); 2013 May; 5(5):335-6. PubMed ID: 23715437
[No Abstract] [Full Text] [Related]
5. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
Pike KG; Malagu K; Hummersone MG; Menear KA; Duggan HM; Gomez S; Martin NM; Ruston L; Pass SL; Pass M
Bioorg Med Chem Lett; 2013 Mar; 23(5):1212-6. PubMed ID: 23375793
[TBL] [Abstract][Full Text] [Related]
6. Metabolic regulation, mitochondria and the life-prolonging effect of rapamycin: a mini-review.
Pan Y; Nishida Y; Wang M; Verdin E
Gerontology; 2012; 58(6):524-30. PubMed ID: 22947849
[TBL] [Abstract][Full Text] [Related]
7. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.
Goutagny S; Raymond E; Esposito-Farese M; Trunet S; Mawrin C; Bernardeschi D; Larroque B; Sterkers O; Giovannini M; Kalamarides M
J Neurooncol; 2015 Apr; 122(2):313-20. PubMed ID: 25567352
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
[TBL] [Abstract][Full Text] [Related]
10. TOR-inhibitors as gero-suppressors.
Nikiforov M
Aging (Albany NY); 2015 Dec; 7(12):1030-1. PubMed ID: 26796970
[No Abstract] [Full Text] [Related]
11. mTOR signaling for biological control and cancer.
Alayev A; Holz MK
J Cell Physiol; 2013 Aug; 228(8):1658-64. PubMed ID: 23460185
[TBL] [Abstract][Full Text] [Related]
12. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
13. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
[TBL] [Abstract][Full Text] [Related]
14. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
[No Abstract] [Full Text] [Related]
15. Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders.
Burket JA; Benson AD; Tang AH; Deutsch SI
Brain Res Bull; 2014 Jan; 100():70-5. PubMed ID: 24295733
[TBL] [Abstract][Full Text] [Related]
16. Dual mTORC1/C2 inhibitors: gerosuppressors with potential anti-aging effect.
Sousa-Victor P; García-Prat L; Muñoz-Cánoves P
Oncotarget; 2015 Sep; 6(27):23052-4. PubMed ID: 26375366
[TBL] [Abstract][Full Text] [Related]
17. Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis.
Ai D; Jiang H; Westerterp M; Murphy AJ; Wang M; Ganda A; Abramowicz S; Welch C; Almazan F; Zhu Y; Miller YI; Tall AR
Circ Res; 2014 May; 114(10):1576-84. PubMed ID: 24687132
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors.
Yoon S; Kim JH; Kim SE; Kim C; Tran PT; Ann J; Koh Y; Jang J; Kim S; Moon HS; Kim WK; Lee S; Lee J; Kim S; Lee J
J Med Chem; 2016 Nov; 59(22):10322-10328. PubMed ID: 27933890
[TBL] [Abstract][Full Text] [Related]
19. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.
Fan Q; Aksoy O; Wong RA; Ilkhanizadeh S; Novotny CJ; Gustafson WC; Truong AY; Cayanan G; Simonds EF; Haas-Kogan D; Phillips JJ; Nicolaides T; Okaniwa M; Shokat KM; Weiss WA
Cancer Cell; 2017 Mar; 31(3):424-435. PubMed ID: 28292440
[TBL] [Abstract][Full Text] [Related]
20. [Subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mTOR inhibitors].
Zitterbart K
Klin Onkol; 2014; 27(6):401-5. PubMed ID: 25493579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
